Iovance Biotherapeutics Inc.
IOVA | NASDAQ
$10.19
-$0.06 (-0.59%)
At close: Sep 21, 2026, 4:00 PM ET
$10.24
+$0.05 (+0.49%)
Pre-market:
Sep 22, 2026, 6:27 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 263.5M | 164.07M | 1.19M | n/a | n/a | n/a |
Cost of Revenue | 7.29M | 124M | 10.76M | n/a | n/a | n/a |
Gross Profit | 256.22M | 40.08M | -9.57M | n/a | n/a | n/a |
Operating Income | -403.36M | -395.28M | -460.56M | -398.88M | -342.7M | -261.94M |
Interest Income | n/a | 20.27M | 13.04M | 2.99M | 451K | 2.36M |
Pretax Income | -393.05M | -375.01M | -447.52M | -395.89M | -342.25M | -259.58M |
Net Income | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M | -259.58M |
Selling & General & Admin | 152.32M | 153.02M | 106.92M | 104.1M | 83.66M | 60.21M |
Research & Development | 300.27M | 282.34M | 344.08M | 294.78M | 259.04M | 201.73M |
Other Expenses | 206.98M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 659.57M | 435.35M | 450.99M | 398.88M | 342.7M | 261.94M |
Interest Expense | n/a | n/a | n/a | 2.99M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 666.86M | 559.35M | 461.75M | 398.88M | 342.7M | 261.94M |
Income Tax Expense | -2.07M | -2.83M | -3.48M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M | 138.3M |
Shares Outstanding (Diluted) | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M | 138.3M |
EPS (Basic) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 |
EPS (Diluted) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 |
EBITDA | -357.11M | -331.4M | -414.39M | -371.77M | -328.27M | -260.8M |
EBIT | -393.05M | -375.01M | -447.52M | -392.91M | -342.25M | -261.94M |
Depreciation & Amortization | 35.94M | 43.61M | 33.13M | 21.14M | 13.98M | 1.14M |
Add to Watchlist
Select watchlists to add or remove IOVA